Somatic Stem Cells

Abstract

A somatic stem cell that is CD10+, CXCR4+, and CD31+ and another somatic stem cell that is CD 105+, CD44+, and nestin+. Also disclosed are both a method of preparing these stem cells and a method of using them to treat degenerative diseases, e.g., a muscle-degenerative disease. The invention further includes making and using liver cells derived from the somatic cell that is CD105+, CD44+, and nestin+.

What is claimed is: 
     
         1 . An isolated somatic stem cell that is CD10+, CXCR4+, and CD31+. 
     
     
         2 . The isolated somatic stem cell of  claim 1 , wherein the isolated somatic stem cell is a non-adherent cell. 
     
     
         3 . The isolated somatic stem cell of  claim 2 , wherein the cell is a human cell. 
     
     
         4 . The isolated somatic stem cell of  claim 3 , wherein the isolated somatic stem cell is pluripotent or multipotent. 
     
     
         5 . An isolated somatic stem cell that is CD105+, CD44+, and Nestin+. 
     
     
         6 . The isolated somatic stem cell of  claim 5 , wherein the isolated somatic stem cell is an adherent cell. 
     
     
         7 . The isolated somatic stem cell of  claim 6 , wherein the cell is a human cell. 
     
     
         8 . The isolated somatic stem cell of  claim 7 , wherein the isolated somatic stem cell is pluripotent or multipotent. 
     
     
         9 . A cell bank comprising a plurality of populations of somatic stem cells, the somatic stem cells each being CD10+, CXCR4+, and CD31+ and the populations being originated from different subjects. 
     
     
         10 . A cell bank comprising a plurality of populations of somatic stem cells, the somatic stem cells each being CD105+, CD44+, and Nestin+ and the populations being originated from different subjects. 
     
     
         11 . A method for treating a muscle injury or a muscle-degenerative disease, the method comprising administering to a subject in need thereof an effective amount of the isolated somatic stem cells of  claim 1 . 
     
     
         12 . A method for treating a muscle injury or a muscle-degenerative disease, the method comprising administering to a subject in need thereof an effective amount of the isolated somatic stem cells of  claim 5 . 
     
     
         13 . A method of preparing somatic stem cells, the method comprising:
 obtaining from a subject a bodily fluid sample containing a plurality of cells,   incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer,   collecting the upper layer,   isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, and   culturing the isolated somatic stem cells in a medium containing R-Spondin-1, SCF, G-CSF, bFGF, EGF, and PDGF.   
     
     
         14 . The method of  claim 13 , wherein the somatic stem cells are CD10+, CXCR4+, and CD31+. 
     
     
         15 . The method of  claim 13 , wherein the somatic stem cells are CD105+, CD44+, and Nestin+. 
     
     
         16 . The method of  claim 13 , wherein the bodily fluid sample is a blood sample or a bone marrow sample. 
     
     
         17 . A method of preparing liver cells from somatic stem cells, the method comprising:
 culturing the isolated somatic stem cell of  claim 5  in a first differentiating medium containing activin;   culturing the isolated somatic stem cell in a second differentiating medium containing basic FGF and BMP2;   culturing the isolated somatic stem cell in a third differentiating medium containing HGF, and DEX, and OSM; and   collecting liver cells thus obtained, the liver cells expressing albumin, transferrin, and HNF3B.   
     
     
         18 . An extracorporeal bioartificial liver device comprising a cartridge that contains an array of hollow fibers and the liver cells prepared by the method of  claim 17  placed in the extracapillary space between the hollow fibers, wherein the hollow fibers are each formed of a membrane having a pore size of 0.1 μm to 0.3 μm. 
     
     
         19 . The device of  claim 18 , wherein the cartridge is in a cylindrical shape having a first opening at one terminus and a second opening on the other terminus; and the first opening is affixed to a first passage and the second opening is affixed to a second passage, the two passages extending away from the cartridge. 
     
     
         20 . A method of treating acute liver failure, the method comprising:
 identifying a subject in need of treatment,   attaching the device of  claim 19  to an artery of the subject through the first passage and a vein of the subject through the second passage,   perfusing blood from the subject through the capillary space inside each of the hollow fibers in the cartridge, and   allowing cleansing of blood by permitting the crossover of toxic solutes from the blood to the liver cells cultured in the extracapillary space between the hollow fibers and also allowing the diffusion of vital metabolites from the liver cells to the blood returning to the subject undergoing treatment.   
     
     
         21 . A method of producing albumin, comprising:
 culturing in a medium the liver cells prepared by the method of  claim 17 , and   collecting from the medium albumin produced by the liver cells.